The safety profile of JS007 monotherapy in this trial was excellent and comparable to that of CTLA-4 antibodies previously reported, regardless of the enrollment of patients with heterogeneous tumor types and multiple prior lines of therapy. The gene discussed is CTLA4; the disease is neoplasm.